Publications by authors named "Dominik Zolnowski"
For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly include triplet regimens based on proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies and since recently also CAR T cells. The importance of autologous salvage transplantation (retransplantation, Re-AHCT) has significantly decreased in recent years due to the availability of many new treatment options.
View Article and Find Full Text PDFArticle Synopsis
- Patients with multiple myeloma and soft-tissue plasmacytoma (STP) have a poor prognosis, despite new treatments and bone marrow transplants.
- A study of 120 STP patients showed a 67% rate of partial response to first-line treatment, with median progression-free survival (PFS) of 10.5 months and overall survival (OS) of 24.5 months.
- Secondary STP and organ involvement were identified as significant negative factors affecting PFS and OS, highlighting the need for customized treatment strategies, including immunotherapies.
Article Synopsis
- Neuroendocrine neoplasia grade 3 (NEN G3) is a rare cancer with poor prognosis; this study analyzed real-world data from the German NET Registry to explore treatment and survival outcomes.* -
- Among the 445 patients examined, 71.5% had advanced stage IV disease, and treatment often involved chemotherapy (43.8%) or surgery (41.6%); the overall median survival was 31 months.* -
- While survival rates appeared better than some population studies, further research is necessary to determine the most effective treatment strategies for specific patient subgroups.*